Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia

Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E.; Ismail, Shaiful B.; Omar, Khairani
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p743
Academic Journal
Background: Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in Malaysia and no recent evidence in Australia is present. We aimed to compare the provision of medicines information by pharmaceutical representatives to doctors in Australia and Malaysia. Methods: Following a pharmaceutical representative's visit, general practitioners in Australia and Malaysia who had agreed to participate, were asked to fill out a questionnaire on the main product and claims discussed during the encounter. The questionnaire focused on provision of product information including indications, adverse effects, precautions, contraindications and the provision of information on the Pharmaceutical Benefit Scheme (PBS) listings and restrictions (in Australia only). Descriptive statistics were produced. Chi-square analysis and clustered linear regression were used to assess differences in Australia and Malaysia. Results: Significantly more approved product information sheets were provided in Malaysia (78%) than in Australia (53%) (P < 0.001). In both countries, general practitioners reported that indications (Australia, 90%, Malaysia, 93%) and dosages (Australia, 76%, Malaysia, 82%) were frequently provided by pharmaceutical representatives. Contraindications, precautions, drug interactions and adverse effects were often omitted in the presentations (range 25% - 41%). General practitioners in Australia and Malaysia indicated that in more than 90% of presentations, pharmaceutical representatives partly or fully answered their questions on contraindications, precautions, drug interactions and adverse effects. More general practitioners in Malaysia (85%) than in Australia (60%) reported that pharmaceutical representatives should have mentioned contraindications, precautions for use, drug interaction or adverse effects spontaneously (P < 0.001). In 48% of the Australian presentations, general practitioners reported the pharmaceutical representatives failed to mention information on PBS listings to general practitioners. Conclusions: Information on indications and dosages were usually provided by pharmaceutical representatives in Australia and Malaysia. However, risk and harmful effects of medicines were often missing in their presentations. Effective control of medicines information provided by pharmaceutical representatives is needed.


Related Articles

  • Bad Medicine. Pinchefsky, Carol // Men's Fitness;Nov2004, Vol. 20 Issue 10, p42 

    Presents information on the side effects of several medicines in the U.S. Accutane; Cardizem; Nexium; Paxil; Ritalin.

  • Things to know about adverse reactions to medicine.  // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1791 

    Provides a general overview on adverse drug reactions. Cause of adverse reactions; Suggestions before taking medicines; Adverse drug reactions that people and doctor might notice after taking the medicine; Management of patient with adverse drug reactions.

  • Diagnosing Nonimmediate Reactions to Penicillins by in vivo Tests. Romano, Antonino; Viola, Marinella; Mondino, Chiara; Pettinato, Rosa; Di Fonso, Marina; Papa, Giuseppe; Venuti, Alberto; Montuschi, Paolo // International Archives of Allergy & Immunology;2002, Vol. 129 Issue 2, p169 

    Background: Maculopapular and urticarial rashes are nonimmediate manifestations common during penicillin treatment; the former often represent cell-mediated hypersensitivity. Our objectives were to assess the incidence of allergy in adults reporting nonimmediate manifestations during penicillin...

  • Characterizing the Network of Drugs and Their Affected Metabolic Subpathways. Chunquan Li; Desi Shang; Yan Wang; Jing Li; Junwei Han; Shuyuan Wang; Qianlan Yao; Yingying Wang; Yunpeng Zhang; Chunlong Zhang; Yanjun Xu; Wei Jiang; Xia Li // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    A fundamental issue in biology and medicine is illustration of the overall drug impact which is always the consequence of changes in local regions of metabolic pathways (subpathways). To gain insights into the global relationship between drugs and their affected metabolic subpathways, we...

  • SFINX—a drug-drug interaction database designed for clinical decision support systems. Böttiger, Ylva; Laine, Kari; Andersson, Marine; Korhonen, Tuomas; Molin, Björn; Ovesjö, Marie-Louise; Tirkkonen, Tuire; Rane, Anders; Gustafsson, Lars; Eiermann, Birgit // European Journal of Clinical Pharmacology;Jun2009, Vol. 65 Issue 6, p627 

    The aim was to develop a drug-drug interaction database (SFINX) to be integrated into decision support systems or to be used in website solutions for clinical evaluation of interactions. Key elements such as substance properties and names, drug formulations, text structures and references were...

  • THE BEST AND WORST DRUGS FOR WOMEN. Davis, Lisa; Burmeier, Beverly; von Bubnoff, Andreas // Prevention;Mar2007, Vol. 59 Issue 3, p167 

    This article explains that women are at increased risk for side effects from prescription drugs. The chemical make up of women contributes to the metabolizing of certain drugs. The author speaks of a gender based medicine where women are required to participate in all federally funded clinical...

  • Why Drug Safety Should Not Take a Back Seat to Efficacy.  // PLoS Medicine;Sep2011, Vol. 8 Issue 9, p1 

    The authors' reflect on the consideration given to the harmful effects from prescription drug use which can cause major adverse drug reactions and deaths. They refer to medical studies that suggest to improve the passive surveillance systems on drug safety concerns. However, the authors reveal...

  • Restrictions on use of promethazine in children.  // WHO Drug Information;2006, Vol. 20 Issue 1, p12 

    The article focuses on the Health Sciences Authority (HSA) and its Pharmacovigilance Advisory Committee's review regarding the safety profile of promethazine in children. It was concluded that the risk of serious adverse drug reactions outweighs the potential benefits of the drug in young...

  • New hypothesis risk tool could offer more answers.  // Medical Marketing & Media;Mar2004, Vol. 39 Issue 3, p16 

    Reports on the United States Food and Drug Administration's (FDA) release of a hypothesis-based drug safety analysis tool. Features of the risk-assessment tool; Drugs used by the FDA as subjects for the hypothesis-based study.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics